Chao Lin

Chao Lin

Auto-generated profile, based on publicly available information

Chao Lin

Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia Medica, Shandong, P. R. of China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2024 in International Journal of Hydrogen Energy
Verified
Journal Article
Closed access
LMLigang Ma
Ligang Ma
CLChao Lin
Chao Lin
WJWenjun Jiang
Wenjun Jiang
LXLe Xu
Le Xu
YSYujie Shao
Yujie Shao
WXWu Xiao
Wu Xiao

13 August 2024 in International Journal of Hydrogen Energy
Verified
Journal Article
Closed access
LMLigang Ma
Ligang Ma
YDYihuan Ding
Yihuan Ding
CLChao Lin
Chao Lin
YYYuqing Yang
Yuqing Yang
LXLe Xu
Le Xu
XAXiaoqian Ai
Xiaoqian Ai

1 June 2021 in Tetrahedron Letters
Verified
Journal Article
Closed access
CLChao Lin
Chao Lin
PLPeiwu Li
Peiwu Li
LWLin Wang
Lin Wang

5 June 2023 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
CLChao Lin
Chao Lin
MWMao‐Chang Wang
Mao‐Chang Wang
PWPeng Wie
Peng Wie
QXQi Xing
Qi Xing
CLChen‐He Liu
Chen‐He Liu

24 May 2021 in RSC Advances
Verified
Journal Article
Open access
PDF file
CLChao Lin
Chao Lin
QXQi Xing
Qi Xing
HXHonglei Xie
Honglei Xie
Herein, we developed an efficient and straightforward method for the rapid synthesis of spirocyclic oxindole scaffolds via the [4 + 1] cyclization reaction of 3-chlorooxindole with o-quinone methides (o-QMs), which were generated under mild conditions. The products could be obtained in excellent yields with numerous types of 3-chlorooxindole. This methodology features mild reaction conditions, high atom-economy and broad substrate scope.

4 March 2022 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
LWLin Wang
Lin Wang
XLXiangping Li
Xiangping Li
YKYing Kong
Ying Kong
FWFurong Wang
Furong Wang
QZQiuyan Zhang
Qiuyan Zhang
RRRong Rong
Rong Rong
Compound 6c was a potent DPP-4 inhibitor designed and synthesized by our group. Previous study indicated that compound 6c had a long terminal half time and could be administrated once a week. In vitro and in vivo biological evaluation showed good antidiabetic activity. For further development, more pharmacokinetic behavior needed to be investigated. In this paper, a rapid and sensitive method for the quantification of compound 6c by UPLC-MS/MS was established and validated. Chromatographic separation was achieved by an Exsil Mono C18 (50 mm * 2 mm, 3 μm) column with gradient elution. Sitagliptin was selected as the internal standard. Multiple reaction monitoring (MRM) was employed in positive mode for the detection of compound 6c and the internal standard. The linear range was 1-1000 ng/mL and the intra-day and inter-day precision and accuracy for compound 6c were within 15%. The recoveries of quality control samples with low, medium and high concentrations were 106.34%, 102.54% and 103.94%, and the corrected matrix effects were 86.47%, 90.11% and 101.66% respectively. The samples were stable under different conditions. The validated method was then successfully applied to pharmacokinetic studies in rats after an oral administration of compound 6c. Results showed that there were significant differences in pharmacokinetic parameters between male and female rats. The elimination half-life (t1/2) of male rats was about 30 hours and that of female rats was about 55 hours. In the dose range of 1.75-7 mg/kg, compound 6c probably exhibited linear pharmacokinetics in rats. Compound 6c could be detected in a variety of tissues, with the highest content in the lung, suggesting the possible effect on lung cancer or other respiratory diseases. The cumulative excretion of compound 6c in urine and feces were extremely low. The comprehensive pharmacokinetics, distribution and excretion results may play an important role in the further development of compound 6c.